Is Pelacarsen delayed???

Quote










J&J just laid off entire cardiovascular side of business. Xarelto has more time left on their patent than Entresto does. We should all be looking for other opportunities.
 



anonymous said:
J&J just laid off entire cardiovascular side of business. Xarelto has more time left on their patent than Entresto does. We should all be looking for other opportunities.
Click to expand...
Being a part of the J&J situation, no one saw that coming. Sure the patent was running out of time but it didn’t necessitate dissolving the entire division. No warning at all. My best advice is to always be ready.
 



Who cares. Worse case I ride it out and get a big severance payout. Some where around 7 or 8 months pay maybe a little more if you figure in bonuses. Probably take 2 or 3 months off and enjoy life. Then find a better job that pays me more. Oh the horrors.
 



Has anyone heard anything new on this? They are stringing us along and we are missing other opportunities. It’s crazy to bring us all to vegas and then layoff a bunch of people isn’t it? The RDs had a meeting a couple weeks ago and the ABLs have one in November. Can anybody share any new news on retention?
 









Looking like 2027 now. You can find articles on Novartis pushing back release of phase 3 data to 2026. It will be at least 9 months after they release the data before they can launch. Not bad for a drug that was suppose to launch in mid year 2025.
 



It’s not just delayed, it’s done. They pushed back the study which most likely means the outcomes are not significant enough to stop trial early. If and when it’s ever launched, other products with better efficacy and better dosing will also be available.
 



It's awesome that people actually believed the CV salesforce would have any chance of bridging the gap from Entresto to pelecarsen. Literally zero chance that was ever happening. Way to drink the Kook-aid people.
 



anonymous said:
Looking like 2027 now. You can find articles on Novartis pushing back release of phase 3 data to 2026. It will be at least 9 months after they release the data before they can launch. Not bad for a drug that was suppose to launch in mid year 2025.
Click to expand...
Not bad?
Are you fucking kidding?
Remember the year-long "production delay" with Inclisiran?
There are myriad reasons why that drug failed, but think about the revenue that was lost with a delayed launch.
Furthermore, there are other Lp(a) medications coming, and every day you're not actively competing is another day you fall further behind.
And with pre-launch education delayed two years, you can expect even deeper reductions in sales.
These keystone cops couldn't find their own asses with both hands.
 



Can’t believe they still have not downsized cv. It’s Feb already. Let’s go! What can they possibly be waiting for? ZS short staffed or something. Still trying to figure out how screwed they are with pelcarsen delay? Waiting for CV town hall Mid Feb? WTH.
 



They are not waiting on anything, these things aren't just thrown together. Likely the new realignment has been set for months, they just had HR give them a date and that's that. Who knows how they determine it, but it's likely end of Q1.
 






I'm sure that they have the realignment set, but they want to squeeze every last cent out of Entresto before it goes generic. They probably have 4 or 5 consulting firms working their magical AI spreadsheets to determine what time to pull the trigger on realignment that will maximize revenue from Entresto and minimizing the expense of the sales force. When the algorithm says its time, then Neil will lift his kilt to reveal Dez with pink slips in his hands....
 



anonymous said:
I'm sure that they have the realignment set, but they want to squeeze every last cent out of Entresto before it goes generic. They probably have 4 or 5 consulting firms working their magical AI spreadsheets to determine what time to pull the trigger on realignment that will maximize revenue from Entresto and minimizing the expense of the sales force. When the algorithm says it’s time, then Neil will lift his kilt to reveal Dez with pink slips in his hands....
Click to expand...
The longer they wait, the more reps quit. This saves them big severance packages which they love I’m sure. They will continue to act like its business as usual, cv is the place to be, we have a great future line that nobody believes is true. After the layoff, they will say how they kept the best of us, the cream of the crop, etc until the next layoff 1-2 years after. We should all be looking right now.
 



anonymous said:
I'm sure that they have the realignment set, but they want to squeeze every last cent out of Entresto before it goes generic. They probably have 4 or 5 consulting firms working their magical AI spreadsheets to determine what time to pull the trigger on realignment that will maximize revenue from Entresto and minimizing the expense of the sales force. When the algorithm says its time, then Neil will lift his kilt to reveal Dez with pink slips in his hands....
Click to expand...
100%
 



anonymous said:
Not bad?
Are you fucking kidding?
Remember the year-long "production delay" with Inclisiran?
There are myriad reasons why that drug failed, but think about the revenue that was lost with a delayed launch.
Furthermore, there are other Lp(a) medications coming, and every day you're not actively competing is another day you fall further behind.
And with pre-launch education delayed two years, you can expect even deeper reductions in sales.
These keystone cops couldn't find their own asses with both hands.
Click to expand...
Think you missed the sarcasm. We are probably proving lPa doesn't really matter that much. Novartis can't launch anything right.
 



Top Bottom
Back
Quote